304.69
-7.67 (-2.46%)
Penutupan Terdahulu | 312.36 |
Buka | 308.45 |
Jumlah Dagangan | 602,620 |
Purata Dagangan (3B) | 330,758 |
Modal Pasaran | 9,517,876,224 |
Harga / Pendapatan (P/E TTM) | 24.11 |
Harga / Pendapatan (P/E Ke hadapan) | 23.87 |
Harga / Jualan (P/S) | 4.52 |
Harga / Buku (P/B) | 10.90 |
Julat 52 Minggu | |
Tarikh Pendapatan | 21 Apr 2025 |
Margin Keuntungan | 19.17% |
Margin Operasi (TTM) | 23.37% |
EPS Cair (TTM) | 12.62 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 7.70% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 49.50% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 18.11% |
Nisbah Semasa (MRQ) | 0.930 |
Aliran Tunai Operasi (OCF TTM) | 608.81 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 464.59 M |
Pulangan Atas Aset (ROA TTM) | 14.86% |
Pulangan Atas Ekuiti (ROE TTM) | 58.42% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Diagnostics & Research (US) | Menurun | Menurun |
Diagnostics & Research (Global) | Menurun | Menurun | |
Stok | Medpace Holdings, Inc. | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 1.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 4.5 |
Purata Bergerak Teknikal | -2.5 |
Osilator Teknikal | -2.5 |
Purata | 0.13 |
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |
|
Sektor | Healthcare |
Industri | Diagnostics & Research |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 19.52% |
% Dimiliki oleh Institusi | 87.63% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 362.00 (Baird, 18.81%) | Pegang |
Median | 344.00 (12.90%) | |
Rendah | 330.00 (Leerink Partners, 8.31%) | Pegang |
Purata | 345.00 (13.23%) | |
Jumlah | 1 Beli, 3 Pegang | |
Harga Purata @ Panggilan | 316.46 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Truist Securities | 10 Apr 2025 | 333.00 (9.29%) | Pegang | 282.33 |
Mizuho | 09 Apr 2025 | 355.00 (16.51%) | Beli | 302.56 |
Leerink Partners | 24 Mar 2025 | 330.00 (8.31%) | Pegang | 330.59 |
Baird | 27 Jan 2025 | 362.00 (18.81%) | Pegang | 350.37 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
18 Mar 2025 | Pengumuman | Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025 |
10 Feb 2025 | Pengumuman | Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |